Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

about

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

Item

http://www.wikidata.org/entity/Q37594238

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Complete response to azacitidi ...... resistant to biochemotherapy.

@en

Complete response to azacitidi ...... resistant to biochemotherapy.

@nl

type

Item

label

Complete response to azacitidi ...... resistant to biochemotherapy.

@en

Complete response to azacitidi ...... resistant to biochemotherapy.

@nl

prefLabel

Complete response to azacitidi ...... resistant to biochemotherapy.

@en

Complete response to azacitidi ...... resistant to biochemotherapy.

@nl

P1476

Complete response to azacitidi ...... resistant to biochemotherapy.

@en

P2093

Andrew W Hahn

http://www.w3.org/2001/XMLSchema#string

Hung T Khong

http://www.w3.org/2001/XMLSchema#string

Randy C Bowen

http://www.w3.org/2001/XMLSchema#string

Thomas W Butler

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells.

Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function.

Aberrant methylation of SPARC in human lung cancers.

Lymphoma in older patients.

P304

122-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2016.1090

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28123744

http://www.w3.org/2001/XMLSchema#string

P932

5245156

http://www.w3.org/2001/XMLSchema#string